SCHEMBL13828216

SCHEMBL13828216

CCC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.55
DRD3 P35462 2/20 0.55
DRD2 P14416 1/20 0.55
KCNN4 O15554 3/20 0.52
GRIN2D O15399 2/20 0.50
GRIN1 Q05586 2/20 0.50
GRIN2A Q12879 2/20 0.50
GRIN2B Q13224 2/20 0.50
GRIN2C Q14957 2/20 0.50
OPRD1 P41143 2/20 0.50
CACNA1F O60840 1/20 0.50
ABCB1 P08183 1/20 0.50
CYP2B6 P20813 1/20 0.50
DRD4 P21917 1/20 0.50
OPRK1 P41145 1/20 0.50
CACNA1D Q01668 1/20 0.50
KCNH2 Q12809 1/20 0.50
CACNA1S Q13698 1/20 0.50
CACNA1C Q13936 1/20 0.50
MRGPRX2 Q96LB1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12883298 0.84 HDAC3 (0.53) OPRM1DRD3DRD2KCNN4GRIN2D
SCHEMBL3658136 0.80 OPRM1 (0.43) OPRM1DRD3DRD2KCNN4GRIN2D
SCHEMBL270134 0.80 MAPT (0.57) OPRM1DRD3DRD2KCNN4GRIN2D
SCHEMBL463621 0.80 OPRM1 (0.53) OPRM1DRD3DRD2GRIN2DGRIN1
SCHEMBL30497944 0.80 OPRM1 (0.53) OPRM1DRD3DRD2KCNN4GRIN2D
SCHEMBL8939158 0.79 KCNN4 (0.48) OPRM1DRD3DRD2KCNN4CYP2C19
SCHEMBL12282314 0.78 OPRM1 (0.51) OPRM1DRD3DRD2KCNN4GRIN2D
SCHEMBL10178224 0.78 CYP1A2 (0.59) OPRM1DRD3DRD2KCNN4GRIN2D
SCHEMBL16359539 0.78 OPRM1 (0.51) OPRM1DRD3DRD2KCNN4GRIN2D
SCHEMBL20607354 0.78 OPRM1 (0.66) OPRM1DRD3DRD2KCNN4GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES AVI BIOPHARMA, INC. (US) 2012-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289457-A1 PEPTIDE OLIGONUCLEOTIDE CONJUGATES SNRPE, SMN1; SMN2, UPF1 OPRM1 3207/4885DRD3 4845/4885DRD2 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.